- Home
- GDV vs HCM Comparison
GDV vs HCM Comparison
Compare GDV & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDV
- HCM
- Stock Information
- Founded
- GDV 2003
- HCM 2000
- Country
- GDV United States
- HCM Hong Kong
- Employees
- GDV N/A
- HCM N/A
- Industry
- GDV Investment Managers
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- GDV Finance
- HCM Health Care
- Exchange
- GDV Nasdaq
- HCM Nasdaq
- Market Cap
- GDV 2.3B
- HCM 2.6B
- IPO Year
- GDV N/A
- HCM N/A
- Fundamental
- Price
- GDV $24.15
- HCM $15.25
- Analyst Decision
- GDV
- HCM Hold
- Analyst Count
- GDV 0
- HCM 1
- Target Price
- GDV N/A
- HCM $19.00
- AVG Volume (30 Days)
- GDV 186.0K
- HCM 84.4K
- Earning Date
- GDV 01-01-0001
- HCM 03-19-2025
- Dividend Yield
- GDV 5.81%
- HCM N/A
- EPS Growth
- GDV N/A
- HCM N/A
- EPS
- GDV N/A
- HCM 0.04
- Revenue
- GDV N/A
- HCM $630,201,000.00
- Revenue This Year
- GDV N/A
- HCM $28.98
- Revenue Next Year
- GDV N/A
- HCM $20.41
- P/E Ratio
- GDV N/A
- HCM $69.52
- Revenue Growth
- GDV N/A
- HCM N/A
- 52 Week Low
- GDV $18.04
- HCM $12.84
- 52 Week High
- GDV $23.00
- HCM $21.92
- Technical
- Relative Strength Index (RSI)
- GDV 45.99
- HCM 50.03
- Support Level
- GDV $23.95
- HCM $14.00
- Resistance Level
- GDV $24.59
- HCM $16.64
- Average True Range (ATR)
- GDV 0.28
- HCM 0.47
- MACD
- GDV 0.07
- HCM -0.12
- Stochastic Oscillator
- GDV 61.40
- HCM 47.35
About GDV Gabelli Dividend & Income Trust of Beneficial Interest
Gabelli Dividend & Income Trust operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of total return on its assets with an emphasis on dividends and income. To achieve its objective, the fund may invest its assets in dividend-paying securities or other income-producing securities. The fund invests in various sectors, in which Financial Services, Food & Beverage, Health Care, Consumer Products, Electronics, and Computer Software & Services and others.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.